- About
- Events
- Resource Center
Archives
How Radiologic Technologists Impact the Diagnosis & Prognosis of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Thank you for attending, we hope you enjoyed this webinar.
Please tell us what you thought about today’s presentation by taking the survey below:
About This Event
How Radiologic Technologists Impact the Diagnosis & Prognosis of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Background
Autosomal Dominant Polycystic Kidney Disease (ADPKD), an inherited progressive kidney disease, is the fourth leading cause of kidney failure in the US. ADPKD has a spectrum of clinical and imaging features that have direct prognostic implications1. Total kidney volume (TKV), adjusted for height and age, has been shown to be the best predictor of kidney function decline; this forms the basis for the Mayo Clinic Imaging Classification (MCIC) of the severity grade of ADPKD1. Radiology’s central role in ADPKD is to aid in the imaging-based diagnosis, prognostication, and monitoring for disease progression1.
Did You Know?- Renal ultrasound is considered the first-line modality for the initial assessment of the kidneys1
- Follow-up studies have shown that height-adjusted TKV is correlated with a future decline in eGFR in patients with typical ADPKD1
- Patients with ADPKD and MCIC 1C, 1D, or 1E are considered high risk for progression to ESKD1
- Join us for this webinar to learn more about the role that radiologic technologists play in the diagnosis and prognosis of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
- The importance of TKV in disease prognosis in ADPKD
- The different imaging modalities for measuring TKV
- Odedra D et al. RadioGraphics. 2023;43(1):1-16.
Featuring
Kristopher Triolo, R.T.(MR), MRSO
Diagnostic Radiology Specialist, OwnerRemote Radiology Solutions*
Kristopher Triolo is a 22-year veteran in diagnostic radiology, including 21 years in MRI and 6 years as MRI Safety Officer, with experience ranging from staff technologist at a small imaging facility to modality director of a large national radiology group. He has worked with radiologists throughout the country to develop imaging protocols and techniques, specializing in image optimization, exam efficiency and patient safety. After his time as an applications specialist, his focus shifted to training and developing the skillset of his fellow MRI technologists and has cross trained and prepared dozens of techs for MRI. Kristopher is also the owner of Remote Radiology Solutions, a consulting and remote acquisition company that is looking to revolutionize the way radiology staffs and operates at the site level.
Moderator
Lisa Voigt, PharmD, BCPS, BCCCP, FASHP
Nephrology Senior Medical Science LiaisonOtsuka Pharmaceutical Development & Commercialization, Inc.*
Lisa Voigt is a PharmD who works as a Medical Science Liaison in Nephrology with Otsuka Pharmaceutical Development & Commercialization, Inc. Prior to joining Otsuka in 2019, Dr Voigt practiced as a Medical Intensive Care Unit and Surgical Intensive Care Unit Pharmacist for 15 years at a tertiary medical center in Buffalo, NY. She earned her Bachelor of Science degree in Pharmaceutics and PharmD from the SUNY Buffalo School of Pharmacy and Pharmaceutical Sciences. She completed a Post-Graduate year 1 Pharmacy Residency and Post-Graduate year 2 Critical Care/Emergency Medicine Pharmacy Residency at the University of Rochester Medical Center in Rochester, NY. Dr Voigt is a Past-President of the New York State Council of Health-system Pharmacists and has served on the Board of Directors for the past 10 years. She is also Past-President of the Western New York Society of Health-system Pharmacists. She is an Adjunct Assistant Professor at SUNY Buffalo, School of Pharmacy and Pharmaceutical Sciences. Dr Voigt holds board certifications in pharmacotherapy as well as critical care pharmacotherapy.
*Kristopher Triolo is a paid consultant of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC). Dr Lisa Voigt is an employee of OPDC.
Registration
Related Events
NephU is supported by Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Otsuka America Pharmaceutical, Inc. (OAPI) - committed supporters of the Kidney Health Community. The information provided through NephU is intended for the educational benefit of health care professionals and others who support care for those with kidney disease and other related conditions. It is not intended as, nor is it a substitute for, medical care, advice, or professional diagnosis. Health care professionals should use their independent medical judgement when reviewing NephU’s educational resources. Users seeking medical advice should consult with a health care professional. No CME or CEU credits are available through any of the resources provided by NephU. Some of the contributors may be paid consultants of OPDC and/or OAPI.©2023 Otsuka Pharmaceutical Development & Commercialization, Inc. All rights reserved. - Events
